Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers
Source abstract
Abstract
Immunostimulating reconstituted influenza virosomes (IRIVs) are liposomes with functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase intercalated in the phospholipid bilayer. Here we address the fusion of IRIVs to artificial supported lipid membranes assembled on polyelectrolyte multilayers on both colloidal particles and planar substrates. The R18 assay is used to prove the IRIV fusion in dependence of pH, temperature and HA concentration. IRIVs display a pH-dependent fusion mechanism, fusing at low pH in analogy to the influenza virus. The pH dependence is confirmed by the Quartz Crystal Microbalance technique. Atomic Force Microscopy imaging shows that at low pH virosomes are integrated in the supported membrane displaying flattened features and a reduced vertical thickness. Virosome fusion offers a new strategy for transferring biological functions on artificial supported membranes with potential applications in targeted delivery and sensing.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Lipid Membrane Structure and Behavior · Influenza Virus Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Medical Physics and Biophysics
Faculty of Medicine
University of Leipzig
04107 Leipzig, Germany
Soft Matter Nanotechnology Group
CIC biomaGUNE
20009 San Sebastián, Spain
Biosurfaces Group
Structural Biology Unit
CIC bioGUNE Technological Park
Surflay Nanotec GmbH
12489 Berlin, Germany
Mymetics SA
1066 Epalinges, Switzerland
Funding
Seventh Framework Programme · Ministerio de Economía y Competitividad
References (27)
Show source-provided references
1. Kammer · Vaccine · 2007 · 25 · 706510.1016/j.vaccine.2007.07.052 ↗
2. Glück · Vaccine · 2003 · 21 · 61110.1016/S0264-410X(02)00567-4 ↗
3. Amacker · Int. Immunol. · 2005 · 17 · 69510.1093/intimm/dxh249 ↗
4. M. Amacker , S.Moese , A.Kammer , A.Helenius and R.Zurbriggen , Delivery Technologies for Biopharmaceuticals , ed. L. Jorgensen and H. N. Nielsen , John Wiley & Sons Ltd , London , 2009
5. Moser · Expert Rev. Vaccines · 2013 · 12 · 77910.1586/14760584.2013.811195 ↗
6. Felnerova · Curr. Opin. Biotechnol. · 2004 · 15 · 51810.1016/j.copbio.2004.10.005 ↗
7. Gaurav · World J. Pharm. Pharm. Sci. · 2014 · 3 · 437
8. Harrison · Nat. Struct. Mol. Biol. · 2008 · 15 · 69010.1038/nsmb.1456 ↗
9. de Bruijn · Vaccine · 2006 · 24 · 662910.1016/j.vaccine.2006.05.035 ↗
10. Douglas · Science · 2006 · 312 · 87310.1126/science.1123223 ↗
11. Moser · Expert Rev. Vaccines · 2011 · 10 · 43710.1586/erv.11.15 ↗
12. Bungener · Vaccine · 2002 · 20 · 228710.1016/S0264-410X(02)00103-2 ↗
13. Lee · Nano Res. · 2010 · 2 · 34910.1007/s12274-009-9033-8 ↗
14. Fischlechner · Angew. Chem., Int. Ed. · 2005 · 44 · 289210.1002/anie.200460763 ↗
15. Fischlechner · Angew. Chem., Int. Ed. · 2007 · 46 · 318410.1002/anie.200603445 ↗
16. Toellner · Clin. Chem. · 2006 · 52 · 157510.1373/clinchem.2005.065789 ↗
17. White · Crit. Rev. Biochem. Mol. Biol. · 2008 · 43 · 18910.1080/10409230802058320 ↗
18. Kim · J. Biochem. Mol. Biol. · 2002 · 35 · 459
19. Johnson · J. Virol. · 1984 · 52 · 23810.1128/JVI.52.1.238-247.1984 ↗
20. Diamanti · Langmuir · 2015 · 31 · 862310.1021/acs.langmuir.5b01731 ↗
21. Domecq · Drug Delivery · 2001 · 8 · 15510.1080/107175401316906928 ↗
22. Buranda · J. Phys. Chem. B · 2010 · 114 · 133610.1021/jp906648q ↗
23. Fischlechner · Soft Matter · 2008 · 4 · 224510.1039/b805754k ↗
24. Kielian · Annu. Rev. Virol. · 2014 · 1 · 17110.1146/annurev-virology-031413-085521 ↗
25. Hamilton · Viruses · 2012 · 4 · 114410.3390/v4071144 ↗
26. Han · Nat. Struct. Biol. · 2001 · 8 · 71510.1038/90434 ↗
27. Haywood · J. Gen. Virol. · 1986 · 67 · 281310.1099/0022-1317-67-12-2813 ↗